IRIS
LADETTO, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.126
EU - Europa 5.039
AS - Asia 3.832
SA - Sud America 883
Continente sconosciuto - Info sul continente non disponibili 306
AF - Africa 149
OC - Oceania 5
Totale 16.340
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.856
RU - Federazione Russa 1.869
SG - Singapore 1.494
IE - Irlanda 1.353
HK - Hong Kong 721
BR - Brasile 677
CN - Cina 614
VN - Vietnam 481
IT - Italia 372
SE - Svezia 319
DE - Germania 288
UA - Ucraina 250
FR - Francia 232
GB - Regno Unito 139
CA - Canada 129
BD - Bangladesh 128
IN - India 91
AR - Argentina 69
FI - Finlandia 65
BJ - Benin 59
ID - Indonesia 54
MX - Messico 54
EC - Ecuador 48
JP - Giappone 39
KR - Corea 37
IQ - Iraq 32
NL - Olanda 30
ZA - Sudafrica 28
CO - Colombia 23
PL - Polonia 23
TR - Turchia 20
AT - Austria 19
CL - Cile 18
VE - Venezuela 18
JM - Giamaica 17
PK - Pakistan 17
EG - Egitto 14
SA - Arabia Saudita 14
CR - Costa Rica 13
UZ - Uzbekistan 13
LT - Lituania 12
ES - Italia 11
PE - Perù 11
PY - Paraguay 11
EE - Estonia 10
MA - Marocco 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
CZ - Repubblica Ceca 9
GT - Guatemala 9
IR - Iran 9
KE - Kenya 9
HN - Honduras 8
NI - Nicaragua 8
DZ - Algeria 7
MY - Malesia 7
PH - Filippine 7
SV - El Salvador 7
TT - Trinidad e Tobago 7
EU - Europa 6
AU - Australia 5
BO - Bolivia 5
GR - Grecia 5
RO - Romania 5
TH - Thailandia 5
BB - Barbados 4
KZ - Kazakistan 4
LB - Libano 4
PT - Portogallo 4
XK - ???statistics.table.value.countryCode.XK??? 4
AZ - Azerbaigian 3
BE - Belgio 3
CI - Costa d'Avorio 3
CW - ???statistics.table.value.countryCode.CW??? 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
JO - Giordania 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
TW - Taiwan 3
UY - Uruguay 3
AL - Albania 2
BN - Brunei Darussalam 2
BS - Bahamas 2
GP - Guadalupe 2
HR - Croazia 2
KW - Kuwait 2
LY - Libia 2
PA - Panama 2
PR - Porto Rico 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
ZM - Zambia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
AW - Aruba 1
BA - Bosnia-Erzegovina 1
Totale 16.026
Salva come PNG Salva come JPEG
Città #
Dublin 1.350
San Jose 777
Hong Kong 719
Council Bluffs 455
Singapore 411
Ashburn 395
Jacksonville 301
Moscow 255
Phoenix 197
Wilmington 197
Lauterbourg 192
Princeton 177
Lawrence 174
Ho Chi Minh City 163
Los Angeles 152
San Mateo 145
Chandler 130
Columbus 129
Beijing 123
Santa Clara 102
New York 100
Hanoi 96
Dallas 86
Buffalo 84
Dearborn 84
São Paulo 60
Cotonou 59
Redondo Beach 48
Houston 43
Atlanta 37
Orem 36
Chicago 35
Novara 34
Toronto 34
Seoul 33
Tokyo 33
Denver 32
Boardman 31
Brooklyn 31
Turin 30
Frankfurt am Main 29
Milan 29
Montreal 28
Piemonte 28
Boston 26
Bremen 26
North Bergen 26
Rio de Janeiro 26
St Louis 26
Chennai 24
Falkenstein 24
Ann Arbor 23
Helsinki 23
Schaumburg 23
Tianjin 23
Warsaw 22
Brasília 21
Haiphong 21
Rome 20
Da Nang 19
Fairfield 19
Guangzhou 19
Mexico City 19
Quito 18
Amsterdam 17
London 17
Nuremberg 17
San Francisco 17
Norwalk 15
Andover 14
Des Moines 14
Miami 14
Philadelphia 14
Stockholm 14
Johannesburg 13
Poplar 13
Shanghai 13
Tashkent 13
Woodbridge 13
Baghdad 12
Mumbai 12
Ninh Bình 12
Thái Bình 12
Vienna 12
Olathe 11
Charlotte 10
Curitiba 10
Guayaquil 10
Las Vegas 10
Porto Alegre 10
Seattle 10
Washington 10
Biên Hòa 9
Brno 9
Hangzhou 9
Lima 9
Manchester 9
Munich 9
Naples 9
Querétaro 9
Totale 8.563
Salva come PNG Salva come JPEG
Nome #
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 151
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib 145
STAble: A novel approach to de novo assembly of RNA-seq data and its application in a metabolic model network based metatranscriptomic workflow 145
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients 144
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 142
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up 141
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 139
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes 131
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia 129
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 128
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients 127
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation 119
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 117
Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network. 117
Genetic and phenotypic attributes of splenic marginal zone lymphoma 115
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 113
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 112
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma 110
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies 110
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 109
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 108
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice 105
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment 105
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 105
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 105
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial 104
COMPARISON OF TWO REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION STRATEGIES FOR MINIMAL RESIDUAL DISEASE EVALUATION IN LYMPHOPROLIFERATIVE DISORDERS: CORRELATION BETWEEN IMMUNOGLOBULIN GENE MUTATION LOAD AND REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION PERFORMANCE 104
THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS IS AN INDEPENDENT PREDICTOR OF PROGRESSION AND OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA 104
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial 102
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 101
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia 100
Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy 100
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma 99
Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes 98
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 98
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 98
The black swan: a case of central nervous system graft-versus-host disease 97
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study 97
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 96
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 95
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib 95
Pharmacotherapy considerations for patients who develop acute kidney injury during cancer therapy 94
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 94
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 92
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients 89
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors 89
CAR-T therapy: the role of the hematopoietic stem cell processing laboratory 88
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 88
Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 87
Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells 86
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients 86
A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease 86
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 85
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network 85
Towards the Definition of a Prognostic Model for Mantle Cell Lymphoma 83
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 83
Spontaneous splenic rupture during induction therapy in acute myeloid leukemia: An unusual case 83
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma 82
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial 82
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. 82
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 82
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 81
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 81
Quality assessment for PCR-based minimal residual disease in Lymphoma: 10 Years of cross-laboratory standardization process within the fondazione italiana linfomi MRD network 81
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 80
Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance 79
Controversies in the treatment of follicular lymphoma 79
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 78
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy 78
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 78
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT 78
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial 77
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial 77
Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma 77
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity 77
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapse/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase 3 trial 77
Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units 76
Droplet Digital PCR Assay for MYD88L265P 76
LOW CD49d AND LONG TELOMERE IDENTIFY A CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET WITH HIGHLY FAVOURABLE OUTCOME 75
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias 75
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020 74
LENALIDOMIDE PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE AND RITUXIMAB IS SAFE AND EFFECTIVE IN UNTREATED, ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE I STUDY BY THE FONDAZIONE ITALIANA LINFOMI 74
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 74
DEL(13q14) LENGTH MATTERS: AN INTEGRATED ANALYSIS OF GENOMIC, FISH AND CLINICAL DATA IN 169 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13q DELETION ALONE OR NORMAL KARYOTYPE 74
TWO MAIN GENETIC PATHWAYS LEAD TO THE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO RICHTER SYNDROME 74
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party 73
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 73
Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 73
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells 73
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 72
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL) 72
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests 72
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network 71
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma 71
ESMO consensus conference on Malignant lymphoma: Management of ‘ultra-high-risk’ patients 71
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma 71
The adulthood of MRD detection in MCL 71
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 71
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 70
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma 70
Totale 9.310
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.383
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.383
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022627 0 0 0 55 47 0 16 16 81 13 172 227
2022/20231.966 179 37 76 18 69 123 41 93 1.251 8 50 21
2023/2024706 17 29 30 12 160 5 176 10 6 16 38 207
2024/20252.233 45 7 41 14 22 217 152 119 805 391 65 355
2025/20267.017 165 212 578 1.113 537 493 1.007 1.127 528 617 407 233
2026/20272.467 302 625 833 707 0 0 0 0 0 0 0 0
Totale 16.340